Predictive factors of metabolic dysfunction associated steatotic liver disease (MASLD) among individuals with cardio-metabolic risk factors, multicenter cross-sectional study, North East Ethiopia

埃塞俄比亚东北部一项多中心横断面研究:具有心血管代谢危险因素的个体中代谢功能障碍相关脂肪肝病(MASLD)的预测因素

阅读:2

Abstract

BACKGROUND: Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly known as NAFLD, is a growing global public health concern, affecting 30–40% of the population. Its epidemiology in sub-Saharan Africa, including Ethiopia, is still under-investigated. This study aimed to assess the prevalence of MASLD and its associated factors among individuals with cardio metabolic risk factors. METHODS: An institution-based cross-sectional study was conducted among adults with cardio metabolic risk factors attending follow-up clinics. Data on clinical, anthropometric, biochemical, and ultrasound findings were collected. Descriptive statistics, bivariate, and multivariable logistic regression analysis was performed to identify factors associated with metabolic dysfunction-associated steatotic liver disease. A p-value of < 0.05 was considered statistically significant. RESULT: The prevalence of MASLD was found to be 28.1%. Females were nearly twice as likely to develop MASLD compared to males (AOR = 1.96; 95% CI: 1.08–3.53; P = 0.026). Individuals with diabetes mellitus were more likely to have MASLD than their non-diabetic counterparts (AOR = 1.71; 95% CI: 1.01–2.87; P = 0.044). Study Participants with abnormal body mass index were almost three times more likely to have MASLD compared to those with normal body mass index (AOR = 2.98; 95% CI: 1.08–8.21; P = 0.034). Abnormal waist circumference (AOR = 2.31; 95% CI: 1.22–4.35; P = 0.009) and high triglyceride levels (AOR = 2.27; 95% CI: 1.36–3.77; P = 0.002) were also independent predictors of MASLD. CONCLUSION AND RECOMMENDATION: Nearly one-third of the study participants had MASLD, with diabetes mellitus, dyslipidaemia, increased waist circumference, and overweight significantly associated with its prevalence. These findings highlight the urgent need for targeted screening and early intervention among individuals with multiple cardio metabolic risk factors to prevent MASLD progression and reduce the risk of liver-related and systemic complications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。